Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Dahl, M.    Nordestgaard, B. G.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in ₁-Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General Population

Morten Dahl, MD; Anne Tybjærg-Hansen, MD, DMSc; Peter Lange, MD, DMSc; Jørgen Vestbo, MD, DMSc; and Børge G. Nordestgaard, MD, DMSc

19 February 2002 | Volume 136 Issue 4 | Pages 270-279

Background: A deteriorating effect of severe ₁-antitrypsin deficiency (ZZ genotype) on lung function is well known, whereas the role of intermediate deficiency (MZ genotype) remains uncertain.

Objective: To test the hypothesis that MZ intermediate ₁-antitrypsin deficiency affects pulmonary function and disease.

Design: Population-based cohort study with 21-year follow-up.

Setting: Copenhagen, Denmark.

Participants: 9187 adults randomly selected from the Danish general population.

Measurements: Plasma ₁-antitrypsin levels, annual decrease in FEV₁, airway obstruction, and hospitalization and mortality from chronic obstructive pulmonary disease (COPD).

Results: 451 participants (4.9%) carried the MZ genotype. Plasma ₁-antitrypsin levels were 31% lower in MZ heterozygotes than in persons with the MM genotype (Student t-test, P < 0.001). Annual decrease in FEV₁ was 25 mL in MZ heterozygotes and 21 mL in persons with the MM genotype (t-test, P = 0.048). Airway obstruction was found in 19% of MZ heterozygotes compared with 15% of MM carriers (chi-square test, P = 0.023); in a logistic regression analysis adjusted for age, sex, and tobacco consumption, the corresponding odds ratio was 1.3 (CI, 1.0 to 1.7). The incidence of hospitalization and mortality from COPD was 32 cases per 10 000 person-years in persons with the MZ genotype and 22 cases per 10 000 person-years in those with the MM genotype (log-rank test, P = 0.063). In a Cox regression model adjusted for age, sex, tobacco use, and FEV₁ at study entry, relative risk for COPD outcomes in persons with the MZ genotype versus persons with the MM genotype was 1.5 (CI, 1.0 to 2.3). All these results were independent of the S and E alleles in this gene and were not affected by cystic fibrosis F508 heterozygosity.

Conclusions: MZ heterozygotes had a slightly greater rate of decrease in FEV₁ and were modestly over-represented among persons with airway obstruction and COPD. In the population at large, MZ heterozygosity may account for a fraction of COPD cases—on the order of 2%, similar to the percentage of persons with COPD who have the severe but rare ZZ genotype.

Editors' Notes Context The clinical importance of 1-antitrypsin heterozygosity is uncertain. Contribution This Danish population-based study followed 9187 participants (451 of whom were heterozygotes) with questionnaires and rep eated pulmonary function testing for up to 18 years. Compared with persons who had the normal (MM) genotype, heterozygotes had a slightly greater rate of decrease in lung function, slightly higher incidence of chronic obstructive pulmonary disease (COPD), and slightly higher occurrence of hospitalization or death from COPD. Implications Because the incidence of 1-antitrypsin heterozygosity in the general population is much higher than that of homozygosity, 1-antitrypsin heterozygosity is a more important public health problem than homozygosity. –The Editors

 

Author and Article Information

From Herlev University Hospital, Herlev; Copenhagen University Hospital and Bispebjerg University Hospital, Copenhagen; and Hvidovre University Hospital, Hvidovre, Denmark.

Acknowledgments: The authors thank Anne-Merete Bengtsen, Charlotte Worm, and Hanne Damm for technical assistance and the participants of the Copenhagen City Heart Study for their willingness to participate.

Grant Support: By the Danish Lung Association, the Danish Heart Foundation, the Danish Medical Research Council, Løvens Kemiske Fabrik's Forskningsfond, and the Beckett Fund.

Requests for Single Reprints: Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev University Hospital, DK-2730 Herlev, Denmark; e-mail, brno{at}herlevhosp.kbhamt.dk.

Current Author Addresses: Drs. Dahl and Nordestgaard: Department of Clinical Biochemistry 54M1, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.

Dr. Tybjærg-Hansen: Department of Clinical Biochemistry KB3011, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen Ø, Denmark.

Drs. Lange and Vestbo: Department of Respiratory Medicine 121, Hvidovre University Hospital, Kettegård Allé 30, DK-2650 Hvidovre, Denmark.

Author Contributions: Conception and design: M. Dahl, A. Tybjærg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.

Analysis and interpretation of the data: M. Dahl, A. Tybjærg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.

Drafting of the article: M. Dahl.

Critical revision of the article for important intellectual content: M. Dahl, A. Tybjærg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.

Final approval of the article: M. Dahl, A. Tybjærg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.

Statistical expertise: M. Dahl, A. Tybjærg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.

Obtaining of funding: A. Tybjærg-Hansen, B.G. Nordestgaard.

Collection and assembly of data: M. Dahl, A. Tybjærg-Hansen, B.G. Nordestgaard.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

Related articles in Annals:

Summaries for Patients
Lung Function and Death from Chronic Obstructive Pulmonary Disease in ₁-Antitrypsin MZ Heterozygotes

Annals 2002 136: I35. [Full Text]  

This article has been cited by other articles:

				S J Marciniak and D A Lomas What can naturally occurring mutations tell us about the pathogenesis of COPD? Thorax, April 1, 2009; 64(4): 359 - 364. [Abstract] [Full Text] [PDF]

				D. Roche, A. Mesner, M. Al Nakib, F. Leonard, and P. Beaune Automated Determination of Serum {alpha}1-Antitrypsin by Antitryptic Activity Measurement Clin. Chem., March 1, 2009; 55(3): 513 - 518. [Abstract] [Full Text] [PDF]

				R. A. Sandhaus, G. Turino, J. Stocks, C. Strange, B. C. Trapnell, E. K. Silverman, S. E. Everett, J. K. Stoller, and for the Medical and Scientific Advisory Committee {alpha}1-Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes: A Cautionary Note Chest, October 1, 2008; 134(4): 831 - 834. [Abstract] [Full Text] [PDF]

				M. Zorzetto, E. Russi, O. Senn, M. Imboden, I. Ferrarotti, C. Tinelli, I. Campo, S. Ottaviani, R. Scabini, A. von Eckardstein, et al. SERPINA1 Gene Variants in Individuals from the General Population with Reduced {alpha}1-Antitrypsin Concentrations Clin. Chem., August 1, 2008; 54(8): 1331 - 1338. [Abstract] [Full Text] [PDF]

				G. E. Silva, S. Guerra, S. Keim, R. A. Barbee, and D. L. Sherrill Longitudinal Decline of Diffusing Capacity of the Lung for Carbon Monoxide in Community Subjects With the PiMZ {alpha}1-Antitrypsin Phenotype Chest, May 1, 2008; 133(5): 1095 - 1100. [Abstract] [Full Text] [PDF]

				M. Brantly Efficient and Accurate Approaches to the Laboratory Diagnosis of {alpha}1-Antitrypsin Deficiency: The Promise of Early Diagnosis and Intervention Clin. Chem., December 1, 2006; 52(12): 2180 - 2181. [Full Text] [PDF]

				A. G. Schwartz and J. C. Ruckdeschel Familial Lung Cancer: Genetic Susceptibility and Relationship to Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 16 - 22. [Abstract] [Full Text] [PDF]

				M. Dahl, C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, and B. G. Nordestgaard The protease inhibitor PI*S allele and COPD: a meta-analysis Eur. Respir. J., July 1, 2005; 26(1): 67 - 76. [Abstract] [Full Text] [PDF]

				M Dahl, B G Nordestgaard, and N Seersholm {alpha}1-Antitrypsin genotype unaffected by age * Authors' reply Thorax, March 1, 2005; 60(3): 258 - 259. [Full Text] [PDF]

				M. E. J. Wadsworth, L. E. Vinall, A. L. Jones, R. J. Hardy, D. B. Whitehouse, S. L. Butterworth, W. S. Hilder, J. U. Lovegrove, and D. M. Swallow Alpha1-Antitrypsin as a Risk for Infant and Adult Respiratory Outcomes in a National Birth Cohort Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 559 - 564. [Abstract] [Full Text] [PDF]

				N Seersholm Pi MZ and COPD: will we ever know? Thorax, October 1, 2004; 59(10): 823 - 825. [Full Text] [PDF]

				C P Hersh, M Dahl, N P Ly, C S Berkey, B G Nordestgaard, and E K Silverman Chronic obstructive pulmonary disease in {alpha}1-antitrypsin PI MZ heterozygotes: a meta-analysis Thorax, October 1, 2004; 59(10): 843 - 849. [Abstract] [Full Text] [PDF]

				M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency J. Exp. Med., May 17, 2004; 199(10): 1391 - 1399. [Abstract] [Full Text] [PDF]

				N. A. Molfino Genetics of COPD Chest, May 1, 2004; 125(5): 1929 - 1940. [Abstract] [Full Text] [PDF]

				D L DeMeo and E K Silverman {alpha}1-Antitrypsin deficiency {middle dot} 2: Genetic aspects of {alpha}1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk Thorax, March 1, 2004; 59(3): 259 - 264. [Abstract] [Full Text] [PDF]

				M Luisetti and N Seersholm {alpha}1-Antitrypsin deficiency {middle dot} 1: Epidemiology of {alpha}1-antitrypsin deficiency Thorax, February 1, 2004; 59(2): 164 - 169. [Abstract] [Full Text] [PDF]

				P. E. Peppard, T. Young, M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. Lange, J. Vestbo, S. Kony, and M. Zureik Nose and Blood Pressure Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 317 - 319. [Full Text] [PDF]

				M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. J Talmud, R. Wright, G. Steiner, M. Syvanne, and S. E Humphries Risk of Ischemic Heart and Ischemic Cerebrovascular Disease Is not Increased in S, Z, and 11478A {alpha}1-Antitrypsin Carriers of The Copenhagen City Heart Study * Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): e55 - 56. [Full Text]

				The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s. [Full Text] [PDF]

				M. Miravitlles, S. Vila, R. Jardi, C. de la Roza, F. Rodriguez-Frias, and R. Vidal Emphysema due to {alpha}-Antitrypsin Deficiency: Familial Study of the YBARCELONA Variant Chest, July 1, 2003; 124(1): 404 - 406. [Abstract] [Full Text] [PDF]

				M. Dahl, A. Tybjaerg-Hansen, H. Sillesen, G. Jensen, R. Steffensen, and B. G. Nordestgaard Blood Pressure, Risk of Ischemic Cerebrovascular and Ischemic Heart Disease, and Longevity in {alpha}1-Antitrypsin Deficiency: The Copenhagen City Heart Study Circulation, February 11, 2003; 107(5): 747 - 752. [Abstract] [Full Text] [PDF]